Latest Lead News

Ark Mines has landed a $4.5 million investment from Queensland’s Critical Minerals and Battery Technology Fund, accelerating development at its Sandy Mitchell rare earths project with production targeted for late 2027.

Kogan.com announces the appointment of three seasoned independent directors as part of a strategic board renewal, while confirming a planned chairman transition in 2026.

Kogan.com Ltd reported robust FY25 growth driven by its core platform, despite setbacks from Mighty Ape's platform migration. The company declared a solid dividend and outlined a cautious but optimistic FY26 outlook.

Kogan.com Ltd reported robust FY25 growth with a 35% increase in active customers and a 20.5% rise in platform sales revenue, offset by a significant goodwill impairment at subsidiary Mighty Ape. The group declared a 7.0 cent final dividend and announced key board changes.

WAM Microcap Limited has outperformed the ASX Small Ordinaries Index for the eighth consecutive year, posting an 18.8% portfolio gain and raising its fully franked dividend to 10.6 cents per share.

Meteoric Resources confirms its Caldeira Rare Earth Project in Brazil remains on track after a disputed environmental council vote was declared invalid. Strong local government support and regulatory assurances underpin confidence in project timelines.

Legacy Minerals has secured NSW Government approval to recommence drilling at its Mt Carrington gold-copper project, unveiling fresh geophysical targets and backed by a recent $7.75 million capital raise.

WAM Microcap Limited reported a robust 27% increase in net profit for FY2025, driven by strong portfolio returns and sustained dividend payments. The company’s investment strategy continues to outperform the market, underpinning an optimistic outlook for micro-cap equities.

Otto Energy has appointed industry veteran Chris Dorros as CEO, signaling a strategic push to leverage his two decades of upstream energy expertise. The move aligns with Otto’s growth ambitions and shareholder value focus.

EVT Group has released an extensive valuation update on its diversified $2.3 billion property portfolio, spotlighting landmark Sydney CBD assets alongside a broad hospitality and entertainment footprint across Australia, New Zealand, and Germany.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.